Background Spondyloarthritis (SpA) is a group of chronic inflammatory rheumatism and it is known to be one of the leading causes of disability.
Objectives This study aimed to investigate the quality of life and the psychological disorders (depression, anxiety and insomnia) in patients with SpA.
Methods A total of 60 patients were included with the diagnosis of SpA meeting the Amor and New York modified criteria, in a prospective study. In a questionnaire, the characteristics of the disease and sociodemographic patient were collected. Also psychiatric assessment was done using the insomnia severity index score (ISI) and the Hospital Anxiety and Depression scale (HAD). In addition, patients answered to the Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire and the SF-12.
Results The sex-ratio (men/women) was 3.28 (46/14), the average age was 37.95 years (18–70). The average duration of disease progression was 11.5 years (1–30). The mean value of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 5.11 and the Bath Ankylosing Spondylitis Functional Index (BASFI) was 5.22. Uveitis was reported in 11.7% of patients, osteoporosis in 35%, enthesitis in 36.7% and coxitis in 36.7%. 78.3% of patients received NSIAD and 30% were treated with biotheraby. On the psychological level, 25% of patients had an anxiety, 20% had depression. According to the ISI, 35% of patients had sub threshold insomnia, 20% had moderate insomnia and 10% had severe insomnia. The mean value of the ASQoL was 9 (0–16). The mean value of the physical health was 37.13 (19.34–60.41) and for the mental health was 41.65 (14.9–60.35). A significant positive correlation was found between the disease activity and the ASQoL (p=0.000), the physical health (p=0.000) and the mental health (p=0.002). Also, we found a significant positive correlation between the BASDAI and depression (p=0.01) and insomnia (p=0.001).
Conclusions SpA is a chronic inflammatory disease that contributes to significant physical disability and decreased quality of life in a significant number of patients. The treatment of those patients must consider the improvement of quality of life, as part of a global approach.
Disclosure of Interest None declared